News
How does Retatrutide work
What is the mechanism of action of Retatrutide? Retatrutide, a new weight loss medication, works by mimicking the hormones in the body that regulate hunger and fullness. Specifically, it is designed to function similarly to three key hormones: glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple action approach of Retatrutide may be the reason behind its significant success in promoting weight loss, according to Dr. Dan Skovronsky, the chief scientific and medical officer at Eli Lilly. By mimicking these hormones, Retatrutide can help individuals prevent overeating, reduce their food intake, and reach a feeling of fullness. Rather than relying on drastic measures like forced thermogenesis or ketosis, this medication offers a more straightforward approach to weight loss. In addition to curbing appetite, Retatrutide also works to suppress cravings and hunger signals that can lead to unhealthy eating habits or cravings for unhealthy foods. Overall, its unique mechanism of action makes it a promising option for those looking to manage their weight more effectively.
Learn more
Retatrutide revolution
Revolutionize Your Weight Loss Journey with Retatrutide: A Breakthrough DrugStruggling with weight loss can be incredibly frustrating for many individuals. While some turn to intense diets and exercise regimens, others seek alternative solutions like medications.Introducing Retatrutide, a groundbreaking new weight loss drug that could potentially change the game in the world of weight loss medications. Clinical studies have shown that this drug boasts an impressive 24% effectiveness rate, offering hope for those who have struggled to shed unwanted pounds.Although the results of trials for Retatrutide are promising, the drug still has to undergo three more trials before receiving approval from the Food and Drug Administration (FDA).While we eagerly anticipate this important milestone, our commitment to providing effective healthcare solutions is unwavering. Once Retatrutide receives FDA approval, we will proudly be the first in Oklahoma to offer this life-changing medication.In this blog, we will delve into the potential benefits that Retatrutide could bring to those seeking to lose weight. Keep reading to learn more about this innovative drug and how it could transform your weight loss journey.Retatrutide, developed by Eli Lilly, the same company behind Mounjaro—a diabetes and obesity medication with proven weight loss benefits—is administered through weekly subcutaneous injections.The drug is currently being assessed for its effectiveness in treating type 2 diabetes, obesity, or a combination of both conditions, with promising results thus far.Retatrutide mimics the actions of three key hormones—glucagon, GIP, and GLP-1—that play vital roles in regulating blood sugar levels, promoting feelings of fullness, and suppressing hunger.In clinical trials involving individuals with type 2 diabetes and a BMI between 25 to 50, participants who received higher doses of Retatrutide experienced dose-dependent weight loss, with significant reductions recorded in both body weight and blood sugar levels.Another study focusing on individuals with obesity and related conditions showed similarly impressive weight loss results with Retatrutide. Participants who took the highest doses of the drug experienced substantial reductions in body weight, showcasing its potential as a viable alternative to bariatric surgery.With such promising outcomes, Retatrutide represents a significant step forward in the quest for effective weight loss solutions. If bariatric surgery is not an option for you, consult with professionals at our weight loss clinic in Oklahoma to explore how Retatrutide and other medications could help you achieve your weight loss goals.
Learn more
Mazdutide a ozempic alternative
Whilst ozempic is the most well known diabetes turned weight loss peptide, there have been a number of products going through trials over the last few years. Tirzepatide and Mounjaro are the 2 most well known but due to the several year process to achieve final approval even these 2 are what you could call old technology. Retratrutide is obviously the most popular and well known of the latest generation of more effective weight loss peptides but there's also a product out of China that's been going through the approval process concurrently with Retratrutide, it's called mazdutide. The product is also a multi approach glp similar to Retratrutide and results have been similar, with both Retratrutide and mazdutide showing significantly better results than Mounjaro and ozempic. This provides an option of switching between both products to avoid having to increase the dosage of one product too much. I.e. if after 3 or 4 months of Retratrutide you have increased dosage from 2mg to 6mg as your body adjusted, rather than increasing to 8mg you switch to an initial low dose of mazdutide and utilise until dosage increases too much then swap back to Retratrutide and start again at low initial dose as your body has reset. This is a cheaper and more effective solution for long term use.
Learn more
Healing peptides available in Australia
Here at weight loss supps we are expanding our range of research chemical peptides and two of the recent additions ate BPC-157 and TB500 or Thymosin. Both of these healing and body protective compounds can be administered singularly or together for even greater results. BPC-157 is one of the most well studied compounds used to assist the healing process and in layman's terms causes the bodies healing mechanisms to rush to the site of the injury and fast track the healing process. TB 500 is particularly effective where inflammation is present and works particularly well with blood vessels and muscles whilst BPC-157 works with tendons extremely well. There is a multitude of feedback from athletes using these products to resolve untreatable golfers elbow, tennis elbow and carpal tunnel in particular. Many athletes stack these two after undergoing knee reconstruction and other similar long term injuries and have significantly shortened their recovery process.
Learn more
Retatrutide effective again
A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Retatrutide, a new injectable drug candidate from Eli Lilly, is delivering stunning weight loss in clinical trials. Doctors are comparing the results so far to bariatric surgery, calling it the "triple G." "Their mind is freed from the burden of trying to control every morsel of food" one doctor said. The clinical trial results for a new, injectable hormone pen have stunned researchers — it's looking stronger than Ozempic or Mounjaro, and nearly on par with bariatric surgery. Results of two separate mid-stage clinical trials of the drug, called retatrutide, which is under development from drugmaker Eli Lilly, were released in the New England Journal of Medicine (NEJM) and The Lancet on Monday. Doctors discussing the results at the American Diabetes Association conference in San Diego were floored by the rapid weight loss that hundreds of people with obesity and diabetes achieved on this investigational drug, as well as the dramatic improvements to their blood sugar, cholesterol, and blood pressure levels. "We have not seen results like this before," said Dr. Ania Jastreboff, director of the Yale Obesity Research Center, and an author of the NEJM paper. Other doctors at the conference agreed that retatrutide could be a groundbreaking drug for both weight loss and Type 2 diabetes management. Conference attendees from around the globe clapped and gasped when the results were announced. "This raises the bar," Dr. Carel Le Roux from University College Dublin, an obesity researcher who was not affiliated with these studies, said during a press conference. "This is way beyond my wildest dreams." Retatrutide: The 'triple G' drug that frees the mind rendering of illuminated brain waves MR.Cole_Photographer/Getty Images Retatrutide is similar to Ozempic, Wegovy, and Mounjaro in that it is a once weekly injection of hormones that change the way we eat, leading to early feelings of fullness and decreased appetite. But unlike Ozempic and Wegovy, which mimic only one hunger-regulating hormone (GLP-1), or Mounjaro, which mimics two hormones (GLP-1 and GIP), retatrutide is a single molecule that mimics three different hunger-regulating hormones: GLP-1, GIP, and glucagon. That "triple G" action, as some scientists termed it at the meeting, seems to have more potent effects on a person's appetite and satisfaction with food. "What our patients express is freedom," Jastreboff said. "Their mind is freed from the burden of trying to control every morsel of food that they put in their mouth for the rest of their lives." In the trial published in the NEJM, patients with obesity who were given the highest weekly dose of retatrutide (12 mg) lost an average of 58 pounds in 11 months. Their weight was still going down even when the trial ended, suggesting that longer, bigger trials yet to be completed may deliver even more impressive weight loss results. Every patient on the highest dose of retatrutide lost at least 5% of their body weight, and a quarter of those participants lost 30% or more of their weight. Eli Lilly's weight-loss drug may prevent diabetes — but there's 1 unanswered question A man rapidly lost weight on a popular weight-loss drug. After 6 months, he was hospitalized with heart problems and confusion. In a similar study of retatrutide for patients with Type 2 diabetes published in The Lancet, patients lost about 17% of their bodyweight in nine months, which is a remarkable feat, since it's typically harder for patients with T2D to lose the same amount of weight as other people with overweight and obesity. Side effects of retatrutide were similar to Ozempic and Mounjaro, including nausea, diarrhea, constipation, and vomiting. Advertisement "This is a real wow," lead Lancet study author Dr. Julio Rosenstock from University of Texas Southwestern Medical Center, said. "Not a single drug has achieved 17% — and you ain't seen nothing yet." Much like Jastreboff's trial, Rosenstock's trial ended while patients were still losing weight. Given more time, Rosenstock said he expects many of those patients with diabetes would achieve 20% weight loss on this drug. Importantly, about a third of the patients with type 2 diabetes on the drug also reverted to normal blood sugar levels while they were on the drug. But it will likely take several years before this drug is commercially available. Before the medication can undergo evaluation by the US Food and Drug Administration, and become available to the public, larger and longer phase 3 clinical trials will need to be successfully completed, a process which will likely take at least until the end of 2025. Read next Health Eli Lilly's weight-loss drug may prevent diabetes — but there's 1 unanswered question Health A man rapidly lost weight on a popular weight-loss drug. After 6 months, he was hospitalized with heart problems and confusion. Health Weight-loss drugs could stave off dementia, small study finds Watch: Ozempic explained: how a miracle diabetes drug became the center of a weight loss craze Weight Loss Diabetes Ozempic
Learn more
Retatrutide breakthrough
SAN DIEGO — An experimental drug from Eli Lilly has the potential to provide greater weight loss benefits than any drug currently on the market. The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds, in a mid-stage clinical trial, the company said Monday from the American Diabetes Association’s annual meeting in San Diego. The findings were simultaneously published in The New England Journal of Medicine. If the results are confirmed in a larger, phase 3 clinical trial — which is expected to run until late 2025 — retatrutide could leapfrog another Lilly weight loss drug, tirzepatide, which experts estimated earlier this year could become the best-selling drug of all time. Tirzepatide is currently approved for Type 2 diabetes under the name Mounjaro; FDA approval of the drug for weight loss is expected this year or early next year
Learn more
